Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

"It has been linked to a variety of medical conditions including cardiovascular disease, stroke, obesity, diabetes, anxiety ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

in a nasal spray and half were given a placebo. The study found those using esketamine had a much greater improvement in depression symptoms at all points over the first four weeks of treatment.

SACRAMENTO — A UC Davis clinic is offering hope to those who are struggling with depression ... Another is esketamine nasal ...

nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management ...